公开(公告)号：US20230240984A1

公开(公告)日：2023-08-03

申请号：US17976737

申请日：2022-10-28

Applicant: Abela Pharmaceuticals, Inc.

Inventor： Colette Cozean ,  Jesse Cozean ,  Rodney Benjamin ,  Anthony Keller

IPC: A61K9/00 ,  A61K31/10 ,  A61K45/06 ,  A61K31/133 ,  A61K31/17 ,  A61K31/4409 ,  A61K31/496 ,  A61K31/4965 ,  A61K31/7036

CPC classification number: A61K9/0053 ,  A61K9/0014 ,  A61K31/10 ,  A61K31/17 ,  A61K31/133 ,  A61K31/496 ,  A61K31/4409 ,  A61K31/4965 ,  A61K31/7036 ,  A61K45/06 ,  Y02A50/30

Abstract: Embodiments of the invention relate generally to the use of formulations comprising DMSO and MSM to treat arthritis (such as osteoarthritis), pain, inflammation, and/or degeneration. DMSO and MSM formulations are administered orally and/or topically in several embodiments and provide effective treatment of both chronic and acute symptoms of arthritis (e.g., osteoarthritis), pain, inflammation, and/or degeneration. Solid forms of DMSO are provided in several embodiments.

公开(公告)号：US20230210854A1

公开(公告)日：2023-07-06

申请号：US17998561

申请日：2021-05-12

Applicant: Recurium IP Holdings, LLC

Inventor： Ahmed Abdi Samatar ,  Jiali Li ,  Peter Qinhua Huang ,  Kevin Duane Bunker ,  Fernando Donate ,  Brant Clayton Boren

IPC: A61K31/519 ,  A61P35/00 ,  A61P11/00 ,  A61P15/00 ,  A61P15/08 ,  A61P1/00 ,  A61P19/08 ,  A61K31/5025 ,  A61K31/7068 ,  A61K31/17 ,  A61K31/282 ,  A61K39/395

CPC classification number: A61K31/519 ,  A61K31/17 ,  A61K31/282 ,  A61K31/5025 ,  A61K31/7068 ,  A61K39/3955 ,  A61P1/00 ,  A61P11/00 ,  A61P15/00 ,  A61P15/08 ,  A61P19/08 ,  A61P35/00

Abstract: Disclosed herein are compounds and combinations of compounds for treating a disease or condition, such as cancer.

公开(公告)号：US11690815B2

公开(公告)日：2023-07-04

申请号：US15970340

申请日：2018-05-03

Applicant: CMPD LICENSING, LLC

Inventor： Jay Richard Ray, II

IPC: A61K31/17 ,  A61K9/00 ,  A61K31/58 ,  A61K9/06 ,  A61K31/573

CPC classification number: A61K31/17 ,  A61K9/0014 ,  A61K9/06 ,  A61K31/573 ,  A61K31/58

Abstract: A method of treating a hyperkeratotic skin condition includes combining contents of a compounded capsule with corticosteroid cream or ointment that includes a high potency corticosteroid to formulate a topical composition for application to a skin area affected by hyperkeratosis. The contents of the capsule may include urea powder, and the corticosteroid cream or ointment may include Clobetasol Propionate Cream or Ointment, Diflorasone Diacetate Cream or Ointment, Amcinonide Cream or Ointment, Betamethasone Dipropionate Cream or Ointment, Desoximetasone Cream or Ointment, Fluocinonide Cream or Ointment, Halcinonide Cream or Ointment, Halobetasol Propionate Cream or Ointment, Mometasone Furoate Cream or Ointment, Flurandrenolide Cream or Ointment, or a combination thereof.

公开(公告)号：US20190192457A1

公开(公告)日：2019-06-27

申请号：US16184922

申请日：2018-11-08

Applicant: Assistance Publique-Hôpitaux de Paris (AP-HP)

Inventor： Michael Frank

IPC: A61K31/17 ,  A61P9/00

CPC classification number: A61K31/17 ,  A61P9/00

Abstract: The present disclosure relates to the field of treatment of an orphan disease, in particular treatment of vascular Ehlers-Danlos syndrome (vEDS). More specifically, the present disclosure relates to novel up-titration dosage regimens (e.g., escalating dosage regimens) effective for treating vEDS patients with celiprolol.

公开(公告)号：US20190008808A1

公开(公告)日：2019-01-10

申请号：US15745639

申请日：2016-08-17

Applicant: Academia Sinica ,  Memorial Sloan Kettering Cancer Center

Inventor： Malcolm Moore ,  Jae-Hung Shieh ,  Tsann-Long Su ,  Te-Chang Lee

IPC: A61K31/167 ,  A61P35/02

CPC classification number: A61K31/167 ,  A61K31/17 ,  A61K45/06 ,  A61P35/02

Abstract: Method of using ureidomustine (BO-1055), a water-soluble NDA cross-linking agent, in the treatment of a cancer, selected from the group consisting of various types of human leukemia [such as acute myeloid leukemia (ALL) and acute B Lymphoblastic leukemia (B-ALL)], lymphomas, small lung cell carcinoma (SCLC), sarcomas, and others.

公开(公告)号：US20180325860A1

公开(公告)日：2018-11-15

申请号：US15777141

申请日：2016-11-17

Applicant: Kip M. CONNOR ,  Eiichi HASEGAWA ,  Bruce D. HAMMOCK ,  Kin Sing Stephen LEE ,  Massachusetts Eye and Ear Infirmary ,  THE REGENTS OF THE UNIVERSITY OF CALIFORNIA

Inventor： Kip M. Connor ,  Eiichi Hasegawa ,  Bruce D. Hammock ,  Kin Sing Stephen Lee

IPC: A61K31/336 ,  A61K9/00 ,  A61P27/06

CPC classification number: A61K31/336 ,  A61K9/0019 ,  A61K9/0048 ,  A61K31/17 ,  A61K31/202 ,  A61K31/445 ,  A61K31/4468 ,  A61K2300/00 ,  A61P27/02 ,  A61P27/04 ,  A61P27/06

Abstract: This disclosure relates to methods of reducing inflammation, angiogenesis, vascular leakage and neovascularization by administering to a subject in need thereof one or more stable analogs of CYP450 lipid metabolites (e.g., eicosanoids) and one or more inhibitors of a soluble epoxide hydrolase (sEH). This disclosure also relates to methods of treating disorders associated with inflammation, angiogenesis, vascular leakage and neovascularization by administering to a subject in need thereof one or more stable analogs of CYP450 lipid metabolites (e.g., eicosanoids) and one or more inhibitors of a soluble epoxide hydrolase (sEH). This disclosure further relates to pharmaceutical compositions and kits comprising at least one stable analog of CYP450 lipid metabolites (e.g., eicosanoids) and at least one inhibitor of a soluble epoxide hydrolase (sEH).

公开(公告)号：US20180250248A1

公开(公告)日：2018-09-06

申请号：US15970340

申请日：2018-05-03

Applicant: CMPD LICENSING, LLC

Inventor： Jay Richard Ray, II

IPC: A61K31/17 ,  A61K9/00 ,  A61K31/573 ,  A61K9/06 ,  A61K31/58

CPC classification number: A61K31/17 ,  A61K9/0014 ,  A61K9/06 ,  A61K31/573 ,  A61K31/58

Abstract: A method of treating a hyperkeratotic skin condition includes combining contents of a compounded capsule with corticosteroid cream or ointment that includes a high potency corticosteroid to formulate a topical composition for application to a skin area affected by hyperkeratosis. The contents of the capsule may include urea powder, and the corticosteroid cream or ointment may include Clobetasol Propionate Cream or Ointment, Diflorasone Diacetate Cream or Ointment, Amcinonide Cream or Ointment, Betamethasone Dipropionate Cream or Ointment, Desoximetasone Cream or Ointment, Fluocinonide Cream or Ointment, Halcinonide Cream or Ointment, Halobetasol Propionate Cream or Ointment, Mometasone Furoate Cream or Ointment, Flurandrenolide Cream or Ointment, or a combination thereof.

公开(公告)号：US20180221313A1

公开(公告)日：2018-08-09

申请号：US15750143

申请日：2016-08-08

Applicant: CENTRE HOSPITALIER NATIONAL D'OPHTALMOLOGIE QUINZE-VINGTS ,  NSTITUT NATINONAL DE LA SANTE ET DE LA RECHERCHE MEDICALE (INSERM) ,  CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE (CNRS) ,  MAGINE INSTITUT DES MALADIES GENETIQUES NECKER ENFANTS MALADES ,  ASSISTANCE PUBLIQUE - HOPITAUX DE PARIS ,  UNIVERSITE PARIS DESCARTES

Inventor： Yves COLIN ,  Jean-Francois GIRMENS ,  Olivier HERMINE ,  Emmanuel HERON ,  Michel PAQUES

IPC: A61K31/17 ,  A61P9/14 ,  A61P27/02

CPC classification number: A61K31/17 ,  A61P9/14 ,  A61P27/02

Abstract: The present invention relates to the use of hydroxycarbamide (HC) for reducing and/or delaying the extension of capillary nonperfusion, a cause of irreparable visual impairment in patients suffering from central retinal vein occlusion (CRVO). This is the first systemic treatment which makes it possible to reduce retinal ischemic complications in patients in whom (CRVO) has been recently diagnosed and is consequently in a rapidly progressive phase. Given the low toxicity of HC evaluated on a large scale in children and adults in the context of other diseases for decades, the results of the present study open up a new therapeutic approach in the treatment of CRVO.

公开(公告)号：US10034887B2

公开(公告)日：2018-07-31

申请号：US15269833

申请日：2016-09-19

Applicant: M.G. Therapeutics, Ltd.

Inventor： Yair Alster ,  Omer Rafaeli ,  K. Angela MacFarlane ,  Cary Reich ,  Shimon Amselem ,  Doron Friedman

IPC: A61K9/00 ,  A61K31/60 ,  A61K33/04 ,  A61K31/327 ,  A61K8/23

CPC classification number: A61K31/60 ,  A61K8/23 ,  A61K9/0014 ,  A61K9/0048 ,  A61K9/06 ,  A61K31/122 ,  A61K31/17 ,  A61K31/19 ,  A61K31/327 ,  A61K31/4015 ,  A61K31/555 ,  A61K33/04 ,  A61K35/04 ,  A61K2300/00

Abstract: Described herein are compositions and methods for the treatment of meibomian gland dysfunction. Said compositions and methods comprise keratolytic agents, such as salicylic acid, selenium disulfide, or the like. Topical administration of said compositions to the eyelid margin or surrounding areas provides therapeutic benefit to patients suffering from meibomian gland dysfunction.

公开(公告)号：US20180200244A1

公开(公告)日：2018-07-19

申请号：US15915637

申请日：2018-03-08

Applicant: The Regents of the University of California

Inventor： Nipavan CHIAMVIMONVAT ,  Bruce D. HAMMOCK

IPC: A61K31/4468 ,  A61K31/4465 ,  A61L31/16 ,  A61L31/00 ,  A61K35/34 ,  A61K31/336 ,  A61K31/195 ,  A61K35/545 ,  A61K9/70 ,  A61K35/28 ,  A61K31/17 ,  A61K31/197 ,  A61K31/22 ,  A61K31/415

CPC classification number: A61K31/4468 ,  A61K9/7023 ,  A61K31/17 ,  A61K31/195 ,  A61K31/197 ,  A61K31/22 ,  A61K31/336 ,  A61K31/415 ,  A61K31/4465 ,  A61K35/28 ,  A61K35/34 ,  A61K35/545 ,  A61L31/005 ,  A61L31/16 ,  A61L2300/432 ,  A61L2300/64 ,  A61L2430/20 ,  A61K2300/00

Abstract: Provided are methods for improving cell-based therapies by co-administration with an agent that increases the production and or levels of epoxygenated fatty acids, as well as kits, stents and patches for co-administering stem cells with an agent that increases the production and/or levels of epoxygenated fatty acids.